Carmila CARM

PAR: CARM | ISIN: FR0010828137 30/04/2025

19,16 EUR (+3,18%)

(+3,18%) 30/04/2025

Grafiek Carmila

Grafiek Carmila

1 dag1d 3,18%
1 week1w 3,88%
1 maand1m 7,40%
3 maanden3m 14,32%
6 maanden6m 10,75%
1 jaar1j 20,20%
5 jaar5j 64,04%

Carmila in het nieuws

Toon enkel gratis nieuws

8 augustus 2024 · Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

9 mei 2024 · Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

8 mei 2024 · Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 · Persbericht

9 november 2023 · Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

14 juni 2023 · Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources · Persbericht

5 juni 2023 · Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023 · Persbericht

11 mei 2023 · Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights · Persbericht

14 april 2023 · Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting · Persbericht

4 april 2023 · Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights · Persbericht

Profiel Carmila

CEO: Alexandre de Palmas

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe